Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

With a projected annual dividend and share buybacks, alongside expectations of production growth as demand rises, Zach believes the company’s valuation and future prospects justify a Buy rating.

These elements, combined with the favorable macroeconomic environment in the Medicare Advantage segment compared to other sectors, justify maintaining a Buy rating on the stock. In another report ...

The company used some of its cash flow to buy back stock. It purchased around ... next two years (slightly above the 19.6% necessary to justify the January 17 closing price), ServiceNow will ...